Adjuvant transarterial chemoembolization for patients after curative resection of hepatocellular carcinoma: a meta-analysis
Authors:
- 22 February 2017
- journal article
- review article
- Published by Taylor & Francis in Scandinavian Journal of Gastroenterology
- Vol. 52 (6-7) , 624-634
Abstract
Objective: To evaluate the efficacy and safety of adjuvant transarterial chemoembolization (TACE) after curative hepatectomy in improving the survival of patients with primary hepatocellular carcinoma (HCC). Methods: MEDLINE, Embase and the Cochrane Library were searched for randomized or nonrandomized studies comparing postoperative adjuvant TACE with curative resection alone. Meta-analysis was performed after converting time-event data into a hazard ratio (HR), using an inverse diversity model. Results: Eight randomized controlled trials (RCTs) and 12 retrospective studies matched the selection criteria, thereby including 3191 patients (779 in RCT, 2412 in observational studies) for the meta-analysis. The meta-analysis showed that receiving adjuvant TACE was associated with improved overall survival (OS, ln[HR] = 0.70, 95%CI: 0.63–0.78, p < .001) and recurrence-free survival (RFS, ln[HR] = 0.69, 95%CI: 0.63–0.76, p < .001) after curative hepatectomies. The results of observational studies were consistent with those of RCTs. Furthermore, meta-regression was utilized to detect study-level factors associated with treatment outcome. It revealed that overall survival was similar among patients treated with various combinations of chemotherapeutic drugs. Subgroup analyses demonstrated that repeated TACE interventions do not provide a higher survival benefit compared with a single course, and patients with a single tumor or tumor size ≥5cm might stand to benefit the most from adjuvant TACE therapy. Conclusions: This meta-analysis demonstrated that postoperative adjuvant TACE could achieve higher OS and RFS than surgical resection alone. However, these results need to be validated through further high-quality clinical studies.Keywords
Funding Information
- Science and Technology Department of Sichuan Province (2017SZ0003 to Y.Z., 2014SZ0039 to J.H.)
- the Key Technology Program of the Science and Technology Bureau of Sichuan Province (2014SZ0039)
- the Key Technology Program of the Science and Technology Bureau of Sichuan Province, China (2017SZ0003)
This publication has 40 references indexed in Scilit:
- The Cochrane Collaboration's tool for assessing risk of bias in randomised trialsBMJ, 2011
- Prognostic factors after early recurrence in patients who underwent curative resection for hepatocellular carcinomaJournal of Surgical Oncology, 2010
- Postoperative adjuvant transarterial chemoembolization for participants with hepatocellular carcinoma: A meta‐analysisHepatology Research, 2010
- Hepatocellular carcinoma: a global viewNature Reviews Gastroenterology & Hepatology, 2010
- A randomized controlled trial of hepatectomy with adjuvant transcatheter arterial chemoembolization versus hepatectomy alone for Stage III A hepatocellular carcinomaJournal of Cancer Research and Clinical Oncology, 2009
- Practical methods for incorporating summary time-to-event data into meta-analysisTrials, 2007
- Postoperative Transhepatic Arterial Chemoembolization and Portal Vein Chemotherapy for Patients with Hepatocellular Carcinoma: A Randomized Study with 131 CasesDigestive Surgery, 2006
- Measuring inconsistency in meta-analysesBMJ, 2003
- Quantifying heterogeneity in a meta‐analysisStatistics in Medicine, 2002
- Randomized study of chemoembolization as an adjuvant therapy for primary liver carcinoma after hepatectomyJournal of Cancer Research and Clinical Oncology, 1995